Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Electrolyte and fluid replacement; dextrose provides caloric support.
ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.
Fluid and electrolyte replenishment,Correction of metabolic acidosis,Intravenous source of calories
Maintenance of fluid and electrolyte balance in patients unable to take oral intake,Correction of metabolic acidosis when bicarbonate is contraindicated or not available,Replacement of electrolytes in hypokalemia, hyponatremia, hypomagnesemia, and hypocalcemia
Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.
Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.
Not applicable; components are endogenous substances. Dextrose has a plasma half-life of approximately 1.5-2.5 hours in normal glucose metabolism; electrolytes have half-lives dependent on renal function (e.g., sodium half-life ~1-2 days).
Not applicable as a single agent; components have variable half-lives (e.g., sodium and chloride distribute rapidly with an elimination half-life of 2-4 hours depending on renal function). In renal impairment, half-life may be prolonged.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are absorbed and excreted by the kidneys.
Acetate and gluconate are metabolized in the liver via the tricarboxylic acid cycle to bicarbonate; electrolytes are distributed in body fluids and excreted renally.
Renal excretion of water and electrolytes; dextrose is metabolized to CO2 and water. >90% of water and electrolytes are excreted renally; dextrose is fully metabolized.
Renal: >95% of administered electrolytes and water are excreted unchanged by the kidneys, primarily as urine. Biliary/fecal: <5% eliminated via feces, mainly unabsorbed components.
Minimal (<5%); electrolytes are not significantly protein-bound; dextrose does not bind to proteins.
Minimal to none: electrolytes like sodium, potassium, chloride, and bicarbonate are not protein-bound (<1%). Magnesium and calcium may have 30-50% binding to albumin, but overall negligible in solution.
Electrolytes distribute to total body water (~0.6 L/kg); dextrose distributes to extracellular fluid initially (~0.2 L/kg) then intracellularly.
Distributes primarily into extracellular fluid (ECF) with Vd approximately 0.2 L/kg for sodium and chloride; calcium and magnesium distribute into a larger volume (0.5-0.6 L/kg) due to intracellular uptake.
Intravenous: 100% bioavailability.
Intravenous: 100% (complete systemic availability). Not administered orally or by other routes for systemic effect.
No specific dose adjustment; monitor fluid and electrolyte status closely in renal impairment due to risk of volume overload and electrolyte disturbances.
Contraindicated in patients with severe renal impairment (GFR < 30 m L/min) due to risk of hyperkalemia. For GFR 30-50 m L/min, reduce infusion rate by 50% and monitor serum potassium closely. No adjustment needed for GFR > 50 m L/min.
No specific dose adjustment; monitor for fluid overload and electrolyte imbalances due to potential altered metabolism.
Child-Pugh Class A: no adjustment. Class B: reduce infusion rate by 25% and monitor serum potassium. Class C: use with caution; consider alternative solutions due to risk of electrolyte imbalance.
Intravenous infusion; rate based on weight: 100 m L/kg/day for first 10 kg, 50 m L/kg/day for next 10 kg, and 20 m L/kg/day for each kg above 20 kg.
Weight-based dosing: 20-30 m L/kg as a single intravenous infusion, administered at a rate not exceeding 5 m L/kg/hour. Maximum total volume: 1000 m L. Adjust based on clinical status and serum electrolytes.
Use with caution; consider lower infusion rates due to decreased renal function and risk of fluid overload; monitor electrolytes and renal function closely.
Elderly patients may require reduced infusion rates (2-5 m L/min) due to decreased renal function and higher risk of fluid overload. Monitor serum potassium and renal function closely.
Not for use in patients with hyperglycemia or certain electrolyte imbalances; solutions containing aluminum may be toxic with prolonged use in renally impaired patients.
None
Monitor serum electrolytes, fluid balance, blood glucose; risk of hyperglycemia, hypokalemia, fluid overload; avoid in patients with renal impairment or heart failure.
Monitor serum electrolytes, fluid balance, and renal function regularly. Use with caution in patients with heart failure, renal impairment, or conditions predisposing to hypervolemia. Avoid rapid infusion; extravasation may cause tissue damage. Contains aluminum, which may accumulate in renal impairment.
Hyperkalemia, hypernatremia, hyperglycemia, severe metabolic acidosis, anuria, or hypersensitivity to any component.
Hyperkalemia, hypernatremia, hypercalcemia, hypermagnesemia, severe metabolic alkalosis, severe renal failure with oliguria or anuria, and patients with a known hypersensitivity to any component.
No direct food interactions. However, dietary intake of electrolytes (e.g., potassium, sodium) should be considered in patients receiving this solution. Avoid high-potassium foods if hyperkalemia is a concern.
No direct food interactions; however, patients should avoid high-potassium foods (e.g., bananas, oranges, tomatoes) if hyperkalemia is a concern. Monitor dietary sodium and fluid intake as per clinical status.
Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/third trimester: use as needed for fluid/electrolyte balance. Dextrose may cause maternal hyperglycemia, which can affect fetal glucose and insulin levels, potentially leading to fetal hyperinsulinism and neonatal hypoglycemia if maternal glucose is poorly controlled.
ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid administration may cause maternal fluid and electrolyte disturbances that can indirectly affect the fetus. Use with caution in the setting of impaired uteroplacental perfusion.
Isolyte R in Dextrose 5% components (dextrose, electrolytes) are normal constituents of breast milk. No known adverse effects. M/P ratio not applicable as dextrose and electrolytes are endogenous substances. Use is considered compatible with breastfeeding.
ISOLYTE E is compatible with breastfeeding. Electrolytes are normally present in breast milk; exogenous administration does not significantly alter infant exposure. M/P ratio not applicable as drug is not a xenobiotic.
No specific dose adjustments required for pregnancy. However, due to increased plasma volume and glomerular filtration rate in pregnancy, individualize based on fluid and electrolyte needs. Monitor for hyperglycemia, which may require dose reduction or insulin therapy. Use caution in preeclampsia or impaired renal function.
No dose adjustment is required for pregnancy. However, pregnant patients may have increased plasma volume and altered renal function; infusion rates should be individualized based on clinical status and serum electrolyte monitoring. Rapid correction of electrolyte imbalances should be avoided to prevent fetal osmotic shifts.
ISOLYTE R in Dextrose 5% is an isotonic solution used for fluid and electrolyte replacement. Monitor serum glucose and electrolytes, especially in diabetic patients. Avoid in patients with hyperglycemia, hyperkalemia, or hyperlactatemia. Use with caution in renal impairment. The solution contains 130 m Eq/L sodium, 4 m Eq/L potassium, 3 m Eq/L calcium, 1 m Eq/L magnesium, 109 m Eq/L chloride, 28 m Eq/L lactate, and 5% dextrose. It provides 170 kcal/L. Do not administer simultaneously with blood products through same line.
ISOLYTE E is a balanced electrolyte solution with 5% dextrose, used for maintenance fluid therapy. Monitor serum potassium closely in renal impairment; contains 20 m Eq/L potassium. Caution in patients with hyperkalemia, renal failure, or metabolic alkalosis. Do not administer simultaneously with blood products due to risk of hemolysis. Observe for signs of fluid overload in patients with heart failure.
Inform your healthcare provider if you have diabetes, kidney problems, or heart failure.,Report any signs of fluid overload (swelling, difficulty breathing) or electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,This solution contains sugar; monitor blood glucose if you have diabetes.,Do not use if the solution is cloudy or contains particles.
This solution is used to replace fluids and electrolytes and provide calories. Tell your doctor if you have kidney problems, heart disease, or are on a low-potassium diet. Report any swelling, shortness of breath, or irregular heartbeat. Do not take over-the-counter potassium supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E IN PLASTIC CONTAINER, answered by our medical review team.
ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Electrolyte and fluid replacement; dextrose provides caloric support.. ISOLYTE E IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by ISOLYTE E is an intravenous electrolyte replacement solution that provides water, electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, and gluconate), and bicarbonate precursors to correct fluid and electrolyte imbalances. The acetate and gluconate ions are metabolized to bicarbonate in the liver, providing an alkaline buffer.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Intravenous Electrolyte Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate based on fluid and electrolyte requirements, typically 1-2 m L/kg/hour for maintenance in adults.. The standard adult dose of ISOLYTE E IN PLASTIC CONTAINER is: Intravenous infusion; rate and volume determined by individual patient requirements for fluid and electrolyte replacement. Typical adult dose: 500-1000 m L as a single infusion, administered at a rate of 5-10 m L/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Dextrose 5% and electrolyte solutions (Isolyte R) are generally considered low risk. No specific teratogenic effects known. First trimester: no evidence of malformations. Second/th. ISOLYTE E IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in plastic container is a balanced electrolyte solution without known teratogenic risk. No fetal harm has been documented in any trimester; however, excessive or rapid ad. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.